Posted inCardiagtech

Hyperthyroidism Differential Diagnosis: A Comprehensive Guide for Clinicians

No Comments

Hyperthyroidism, characterized by excessive thyroid hormone production, is a prevalent endocrine disorder with diverse underlying causes. Early and accurate diagnosis is crucial due to the significant short and long-term health implications associated with this condition. While the hallmark of hyperthyroidism is elevated thyroid hormones, pinpointing the specific etiology is essential for appropriate management. This article provides a comprehensive overview of the differential diagnosis of hyperthyroidism, emphasizing the key factors clinicians should consider to distinguish between various causes and guide effective treatment strategies.

Understanding Hyperthyroidism and Thyrotoxicosis

It’s important to clarify the terms often used interchangeably: hyperthyroidism and thyrotoxicosis. Hyperthyroidism specifically refers to the overproduction of thyroid hormones by the thyroid gland. Thyrotoxicosis, on the other hand, is the clinical syndrome resulting from excessive thyroid hormones in the body, regardless of the source. While hyperthyroidism is a common cause of thyrotoxicosis, other conditions can also lead to elevated thyroid hormone levels. For practical purposes, this discussion will encompass both terms, focusing on the diagnostic challenges in differentiating the underlying causes of elevated thyroid hormones.

Hyperthyroidism can be further classified as overt or subclinical. Overt hyperthyroidism is characterized by suppressed thyroid-stimulating hormone (TSH) levels alongside elevated triiodothyronine (T3) and/or thyroxine (T4) levels. In contrast, subclinical hyperthyroidism presents with low or suppressed TSH but normal T3 and T4 levels. Both forms can lead to significant health complications if left unaddressed, underscoring the importance of accurate differential diagnosis and timely intervention.

Etiologies of Hyperthyroidism and Differential Clues

The differential diagnosis of hyperthyroidism is broad, encompassing various etiologies. The most common causes include:

  1. Graves’ Disease (GD): An autoimmune disorder where antibodies stimulate the TSH receptor, leading to thyroid hormone overproduction and gland enlargement. GD is the leading cause of hyperthyroidism in iodine-sufficient regions and typically affects younger to middle-aged adults. Key differential clues include the presence of Graves’ ophthalmopathy (eye disease) and pretibial myxedema (skin changes on the shins), though these are not always present.

  2. Toxic Multinodular Goiter (TMNG): Characterized by autonomously functioning nodules within an enlarged thyroid gland. TMNG is more prevalent in older individuals and iodine-deficient regions. Palpation of multiple nodules in a goiter is a significant differential clue.

  3. Toxic Adenoma (TA): A single, autonomously functioning thyroid nodule that overproduces thyroid hormones. Similar to TMNG, it’s more common in older populations. Physical exam may reveal a solitary thyroid nodule.

Less common etiologies to consider in the differential diagnosis include:

  • Thyroiditis: Inflammation of the thyroid gland leading to transient thyrotoxicosis due to hormone release. Different types of thyroiditis exist, each with unique features:

    • Subacute Thyroiditis (De Quervain’s Thyroiditis): Often preceded by a viral infection, characterized by neck pain and tenderness, and typically presents with low thyroid uptake on radioactive iodine scan.
    • Painless Thyroiditis (Silent Thyroiditis): An autoimmune condition, often postpartum, with a painless goiter and low thyroid uptake.
    • Hashimoto’s Thyroiditis (Hyperthyroid Phase – Hashitoxicosis): In the early stages of Hashimoto’s, thyroiditis can cause transient hyperthyroidism before progressing to hypothyroidism.
    • Infectious Thyroiditis (Suppurative Thyroiditis): Rare bacterial or fungal infection of the thyroid, causing pain, fever, and often requiring drainage.
    • Drug-Induced Thyroiditis: Certain medications like amiodarone and interferon-alpha can induce thyroiditis. Amiodarone-induced thyrotoxicosis (AIT) is categorized into two types: Type 1 (iodine-induced in pre-existing thyroid disease) and Type 2 (destructive thyroiditis).

  • Iodine-Induced Hyperthyroidism (Jod-Basedow Phenomenon): Excessive iodine intake, often from contrast media or medications, can trigger hyperthyroidism, particularly in individuals with underlying thyroid conditions or iodine deficiency.

  • Factitious Thyrotoxicosis: Ingestion of exogenous thyroid hormone, often for weight loss, leading to suppressed TSH and elevated thyroid hormones with low thyroid uptake.

  • TSH-Secreting Pituitary Adenoma: A rare pituitary tumor that secretes excessive TSH, causing secondary hyperthyroidism.

  • Struma Ovarii: A rare condition where ovarian teratoma contains thyroid tissue that becomes hyperactive, leading to thyrotoxicosis.

  • hCG-Mediated Hyperthyroidism: Elevated human chorionic gonadotropin (hCG) levels, particularly in gestational trophoblastic disease or hyperemesis gravidarum, can weakly stimulate the TSH receptor, causing mild hyperthyroidism.

Epidemiology and Risk Factors in Differential Diagnosis

Epidemiological factors can provide clues in the differential diagnosis. Graves’ disease is more common in younger to middle-aged women, while toxic multinodular goiter and toxic adenoma are more frequent in older individuals. Iodine deficiency increases the risk of nodular thyroid diseases, whereas iodine sufficiency is associated with autoimmune thyroid disorders like Graves’ disease. Amiodarone-induced thyrotoxicosis is relevant in patients taking amiodarone for cardiac arrhythmias. A thorough medication history is crucial to rule out factitious thyrotoxicosis and drug-induced causes.

Pathophysiology and Diagnostic Differentiation

Understanding the pathophysiology of each etiology aids in differential diagnosis:

  • Graves’ Disease: Autoantibodies stimulate TSH receptors. Diagnostic tests reveal elevated thyroid-stimulating immunoglobulins (TSI) or thyrotropin receptor antibodies (TRAb).

  • Toxic Multinodular Goiter and Toxic Adenoma: Somatic mutations in the TSH receptor gene lead to autonomous function. Radioactive iodine uptake scans show increased uptake in nodules, while TRAb levels are negative.

  • Thyroiditis: Thyroid inflammation leads to hormone release. Radioactive iodine uptake is typically low in most forms of thyroiditis (except in the early phase of Hashimoto’s). Subacute thyroiditis is characterized by pain and elevated inflammatory markers.

  • Iodine-Induced Hyperthyroidism: Excess iodine overwhelms thyroid autoregulation. History of iodine exposure and suppressed thyroid uptake can be helpful.

  • Factitious Thyrotoxicosis: Exogenous hormone intake suppresses thyroid function. Thyroid uptake is very low or absent, and thyroglobulin levels are typically low.

  • TSH-Secreting Pituitary Adenoma: Pituitary MRI may reveal a tumor. Elevated TSH along with elevated T4 and T3 is suggestive, requiring further endocrine evaluation.

  • Struma Ovarii: Pelvic imaging might detect an ovarian mass. Thyroid uptake scan will show low uptake in the neck but potentially uptake in the pelvis.

History, Physical Examination, and Differential Diagnosis

A detailed history and physical examination are crucial first steps in differentiating hyperthyroidism etiologies:

History:

  • Symptom Onset and Duration: Abrupt onset with neck pain suggests subacute thyroiditis. Gradual onset is typical for Graves’ disease or toxic nodular goiter.
  • Associated Symptoms: Eye symptoms (Graves’ ophthalmopathy), skin changes (pretibial myxedema) point towards Graves’ disease. Neck pain and tenderness suggest thyroiditis.
  • Medication History: Amiodarone, lithium, interferon, and exogenous thyroid hormone use are important considerations. Iodine exposure history is relevant for Jod-Basedow phenomenon.
  • Past Medical History: Pre-existing thyroid disease, autoimmune conditions, and cardiac history are pertinent.
  • Family History: Family history of thyroid disorders, especially Graves’ disease, increases the likelihood of autoimmune hyperthyroidism.

Physical Examination:

  • Thyroid Palpation:
    • Diffuse Goiter (often with bruit): Graves’ disease.
    • Multinodular Goiter: Toxic multinodular goiter.
    • Solitary Nodule: Toxic adenoma.
    • Tender Thyroid: Subacute thyroiditis or infectious thyroiditis.
    • Painless Goiter or No Goiter: Painless thyroiditis, factitious thyrotoxicosis, early Graves’ disease.
  • Eye Examination: Lid lag, lid retraction (hyperadrenergic signs seen in all hyperthyroidism types), proptosis, diplopia, conjunctival injection (Graves’ ophthalmopathy).
  • Skin Examination: Pretibial myxedema (Graves’ disease).
  • Cardiovascular Examination: Tachycardia, atrial fibrillation, hypertension (common in all hyperthyroidism types).
  • Neurological Examination: Tremors, hyperreflexia (common in all hyperthyroidism types).

Diagnostic Evaluation for Differential Diagnosis

Laboratory and imaging studies are essential to confirm hyperthyroidism and differentiate its causes:

Initial Thyroid Function Tests:

  • TSH, Free T4, Total T3: Confirm the presence and severity of hyperthyroidism. Differentiate overt from subclinical hyperthyroidism and T3 toxicosis.

Etiology-Specific Tests:

  • Thyrotropin Receptor Antibodies (TRAb) or Thyroid-Stimulating Immunoglobulins (TSI): Elevated levels are diagnostic for Graves’ disease.

  • Radioactive Iodine Uptake and Scan (RAIU): Crucial for differentiating causes:

    • High Diffuse Uptake: Graves’ disease.
    • High Patchy Uptake: Toxic multinodular goiter.
    • High Focal Uptake (Hot Nodule): Toxic adenoma.
    • Low Uptake: Thyroiditis (subacute, painless, amiodarone-induced type 2), factitious thyrotoxicosis, iodine-induced hyperthyroidism.

  • Thyroid Ultrasound with Doppler:

    • Increased Vascularity (“Thyroid Inferno”): Graves’ disease. Can also be increased in Type 1 AIT.
    • Decreased Vascularity: Thyroiditis (subacute, painless, amiodarone-induced type 2).
    • Nodules: Help characterize nodular disease (TMNG, toxic adenoma).

  • Thyroglobulin Levels:

    • Elevated: Graves’ disease, toxic nodular goiter, toxic adenoma, thyroiditis (hormone release from the gland).
    • Low: Factitious thyrotoxicosis (suppressed endogenous thyroid hormone production).

  • Inflammatory Markers (ESR, CRP): Elevated in subacute thyroiditis.

  • Pituitary MRI: If TSH-secreting pituitary adenoma is suspected (elevated TSH with elevated thyroid hormones).

  • Beta-hCG: Consider in pregnant women or those with hyperemesis gravidarum if hCG-mediated hyperthyroidism is suspected.

Figure: Evaluation Algorithm for Hyperthyroidism Differential Diagnosis

Evaluation Algorithm, Hyperthyroidism. This image is an algorithm to help providers evaluate patients presenting with hyperthyroidism. Contributed by J Kaur, MD

Differential Diagnosis and Treatment Implications

Accurate differential diagnosis is paramount as treatment strategies vary significantly depending on the underlying cause:

  • Graves’ Disease: Treatment options include antithyroid drugs (methimazole, propylthiouracil), radioactive iodine therapy, and thyroidectomy. The choice depends on patient factors and preferences.

  • Toxic Multinodular Goiter and Toxic Adenoma: Radioactive iodine therapy and thyroidectomy are definitive treatments. Antithyroid drugs can be used for symptom control but are not typically used for long-term management.

  • Thyroiditis: Treatment is often supportive, focusing on symptom management with beta-blockers for hyperadrenergic symptoms and pain control for subacute thyroiditis. Antithyroid drugs are generally not effective and may worsen thyroiditis-induced hyperthyroidism. In severe cases of subacute thyroiditis, corticosteroids may be used.

  • Iodine-Induced Hyperthyroidism: Management involves withdrawing excess iodine exposure and potentially using antithyroid drugs or perchlorate to block thyroid hormone synthesis.

  • Factitious Thyrotoxicosis: Requires identifying and addressing the underlying cause of exogenous hormone intake.

  • TSH-Secreting Pituitary Adenoma: Treatment involves surgical removal of the pituitary tumor, radiation therapy, or medications like somatostatin analogs.

  • Struma Ovarii: Surgical removal of the ovarian tumor is the primary treatment.

Differential Diagnosis in Specific Clinical Scenarios

  • Hyperthyroidism with Eye Signs: Graves’ disease is the most likely diagnosis. However, lid lag and retraction can occur in any hyperthyroid state due to hyperadrenergic effects. True Graves’ ophthalmopathy (proptosis, diplopia, etc.) is specific to Graves’ disease.

  • Hyperthyroidism with Painful Thyroid: Subacute thyroiditis is the primary consideration. Infectious thyroiditis is less common but should be considered, especially with fever and systemic illness.

  • Hyperthyroidism with Low Thyroid Uptake: Suggests thyroiditis, factitious thyrotoxicosis, or iodine-induced hyperthyroidism. Differentiating between these requires clinical context, medication history, thyroglobulin levels, and inflammatory markers.

  • Hyperthyroidism in a Patient on Amiodarone: Amiodarone-induced thyrotoxicosis is highly likely. Differentiating between type 1 and type 2 AIT is crucial for treatment. Type 1 often requires antithyroid drugs and perchlorate, while type 2 may respond to corticosteroids. Thyroid ultrasound with Doppler and RAIU can help distinguish between the types, though RAIU is often suppressed in both types in chronic amiodarone use.

Conclusion

The differential diagnosis of hyperthyroidism is a critical aspect of clinical management. A systematic approach involving detailed history, thorough physical examination, appropriate laboratory and imaging studies is essential to accurately identify the underlying etiology. By considering the clinical presentation, epidemiological factors, pathophysiological mechanisms, and diagnostic test results, clinicians can effectively differentiate between the various causes of hyperthyroidism and tailor treatment strategies to optimize patient outcomes. This comprehensive understanding of hyperthyroidism differential diagnosis empowers healthcare professionals to provide precise and personalized care for patients with this common endocrine disorder.

References

1.Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421. [PubMed: 27521067]
2.Biondi B, Cooper DS. Subclinical Hyperthyroidism. N Engl J Med. 2018 Jun 21;378(25):2411-2419. [PubMed: 29924956]
3.Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccà L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000 Dec;85(12):4701-5. [PubMed: 11134131]
4.Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011 May;96(5):1344-51. [PubMed: 21346066]
5.Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, Faber J, Hansen PR, Pedersen OD, Torp-Pedersen C, Gislason GH. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012 Nov 27;345:e7895. [PMC free article: PMC3508199] [PubMed: 23186910]
6.Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006 Mar 01;295(9):1033-41. [PMC free article: PMC1387822] [PubMed: 16507804]
7.Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C, Gislason GH. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014 Jul;99(7):2372-82. [PubMed: 24654753]
8.Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid. 2001 May;11(5):493-500. [PubMed: 11396708]
9.Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999 Feb;84(2):476-86. [PubMed: 10022404]
10.Mittra ES, Niederkohr RD, Rodriguez C, El-Maghraby T, McDougall IR. Uncommon causes of thyrotoxicosis. J Nucl Med. 2008 Feb;49(2):265-78. [PubMed: 18199610]
11.Dunzendorfer T, deLas Morenas A, Kalir T, Levin RM. Struma ovarii and hyperthyroidism. Thyroid. 1999 May;9(5):499-502. [PubMed: 10365682]
12.Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018 May;14(5):301-316. [PubMed: 29569622]
13.Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009 Jul;25(7):421-4. [PMC free article: PMC2723027] [PubMed: 19584973]
14.Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):723-33. [PubMed: 19942149]
15.Illouz F, Braun D, Briet C, Schweizer U, Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014 Sep;171(3):R91-9. [PubMed: 24833135]
16.Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007 Dec;36(4):1051-66; x-xi. [PMC free article: PMC2134787] [PubMed: 17983936]
17.Guaraldi F, La Selva R, Samà MT, D’Angelo V, Gori D, Fava P, Fierro MT, Savoia P, Arvat E. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest. 2018 May;41(5):549-556. [PubMed: 29043574]
18.Iddah MA, Macharia BN. Autoimmune thyroid disorders. ISRN Endocrinol. 2013;2013:509764. [PMC free article: PMC3710642] [PubMed: 23878745]
19.Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003 Jun 26;348(26):2646-55. [PubMed: 12826640]
20.Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med. 2016 Oct 20;375(16):1552-1565. [PubMed: 27797318]
21.Vitti P, Rago T, Tonacchera M, Pinchera A. Toxic multinodular goiter in the elderly. J Endocrinol Invest. 2002;25(10 Suppl):16-8. [PubMed: 12508907]
22.Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991 May;229(5):415-20. [PubMed: 2040867]
23.Abraham-Nordling M, Byström K, Törring O, Lantz M, Berg G, Calissendorff J, Nyström HF, Jansson S, Jörneskog G, Karlsson FA, Nyström E, Ohrling H, Orn T, Hallengren B, Wallin G. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011 Dec;165(6):899-905. [PubMed: 21908653]
24.Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014 Mar;99(3):923-31. [PubMed: 24423323]
25.Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994 Jun 16;330(24):1731-8. [PubMed: 7910662]
26.Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003 Feb;24(1):102-32. [PubMed: 12588812]
27.Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977 Dec;7(6):481-93. [PubMed: 598014]
28.Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68. [PubMed: 7641412]
29.Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002 Feb;87(2):489-99. [PubMed: 11836274]
30.Wang C, Li Y, Teng D, Shi X, Ba J, Chen B, Du J, He L, Lai X, Li Y, Chi H, Liao E, Liu C, Liu L, Qin G, Qin Y, Quan H, Shi B, Sun H, Tang X, Tong N, Wang G, Zhang JA, Wang Y, Xue Y, Yan L, Yang J, Yang L, Yao Y, Ye Z, Zhang Q, Zhang L, Zhu J, Zhu M, Shan Z, Teng W. Hyperthyroidism Prevalence in China After Universal Salt Iodization. Front Endocrinol (Lausanne). 2021;12:651534. [PMC free article: PMC8194401] [PubMed: 34122333]
31.Bogazzi F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E. Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest. 2012 Mar;35(3):340-8. [PubMed: 22433945]
32.Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, Pacchiarotti A, Aronin N, Macchia E, Haffajee C. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984 Jul;101(1):28-34. [PubMed: 6428291]
33.Krohn K, Führer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev. 2005 Jun;26(4):504-24. [PubMed: 15615818]
34.Hamburger JI. Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab. 1980 Jun;50(6):1089-93. [PubMed: 7372787]
35.Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Vidor G, Braverman LE, Medeiros-Neto G. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid. 1998 Jan;8(1):83-100. [PubMed: 9492158]
36.Bervini S, Trelle S, Kopp P, Stettler C, Trepp R. Prevalence of Iodine-Induced Hyperthyroidism After Administration of Iodinated Contrast During Radiographic Procedures: A Systematic Review and Meta-Analysis of the Literature. Thyroid. 2021 Jul;31(7):1020-1029. [PubMed: 33327840]
37.Dunne P, Kaimal N, MacDonald J, Syed AA. Iodinated contrast-induced thyrotoxicosis. CMAJ. 2013 Feb 05;185(2):144-7. [PMC free article: PMC3563887] [PubMed: 23148056]
38.Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore). 1983 Jan;62(1):1-20. [PubMed: 6218369]
39.Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010 Jun;95(6):2529-35. [PubMed: 20525904]
40.Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN., American Thyroid Association. American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun;21(6):593-646. [PubMed: 21510801]
41.Şahlı E, Gündüz K. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol. 2017 Apr;47(2):94-105. [PMC free article: PMC5384127] [PubMed: 28405484]
42.Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM., EUGOGO † The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. [PubMed: 34297684]
43.Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010 Feb 25;362(8):726-38. [PMC free article: PMC3902010] [PubMed: 20181974]
44.Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005;6(5):295-309. [PubMed: 16252929]
45.Jadidi J, Sigari M, Efendizade A, Grigorian A, Lehto SA, Kolla S. Thyroid acropachy: A rare skeletal manifestation of autoimmune thyroid disease. Radiol Case Rep. 2019 Aug;14(8):917-919. [PMC free article: PMC6536614] [PubMed: 31193617]
46.Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab. 2002 Dec;87(12):5435-41. [PubMed: 12466333]
47.De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016 Aug 27;388(10047):906-918. [PMC free article: PMC5014602] [PubMed: 27038492]
48.Favresse J, Burlacu MC, Maiter D, Gruson D. Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm. Endocr Rev. 2018 Oct 01;39(5):830-850. [PubMed: 29982406]
49.Li D, Radulescu A, Shrestha RT, Root M, Karger AB, Killeen AA, Hodges JS, Fan SL, Ferguson A, Garg U, Sokoll LJ, Burmeister LA. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA. 2017 Sep 26;318(12):1150-1160. [PMC free article: PMC5818818] [PubMed: 28973622]
50.McKee A, Peyerl F. TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis. Am J Manag Care. 2012 Jan 01;18(1):e1-14. [PubMed: 22435785]
51.Autilio C, Morelli R, Locantore P, Pontecorvi A, Zuppi C, Carrozza C. Stimulating TSH receptor autoantibodies immunoassay: analytical evaluation and clinical performance in Graves’ disease. Ann Clin Biochem. 2018 Jan;55(1):172-177. [PubMed: 28388869]
52.Kahaly GJ. Bioassays for TSH Receptor Antibodies: Quo Vadis? Eur Thyroid J. 2015 Mar;4(1):3-5. [PMC free article: PMC4404890] [PubMed: 25960955]
53.Chung J, Lee YJ, Choi YJ, Ha EJ, Suh CH, Choi M, Baek JH, Na DG., Korean Society of Thyroid Radiology (KSThR). Korean Society of Radiology. Clinical applications of Doppler ultrasonography for thyroid disease: consensus statement by the Korean Society of Thyroid Radiology. Ultrasonography. 2020 Oct;39(4):315-330. [PMC free article: PMC7515666] [PubMed: 32892523]
54.Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2001 Jan;86(1):3-8. [PubMed: 11231968]
55.Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012 Dec;97(12):4549-58. [PubMed: 23043191]
56.Balazs C, Kiss E, Leövey A, Farid NR. The immunosuppressive effect of methimazole on cell-mediated immunity is mediated by its capacity to inhibit peroxidase and to scavenge free oxygen radicals. Clin Endocrinol (Oxf). 1986 Jul;25(1):7-16. [PubMed: 3024872]
57.Lechpammer M, Lukac J, Lechpammer S, Kusić Z. Antithyroid drug-induced immunomodulation in Graves’ disease patients. Acta Med Croatica. 2002;56(1):21-6. [PubMed: 12455450]
58.Laurberg P, Andersen SL. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Eur J Endocrinol. 2014 Jul;171(1):R13-20. [PubMed: 24662319]
59.Hackmon R, Blichowski M, Koren G. The safety of methimazole and propylthiouracil in pregnancy: a systematic review. J Obstet Gynaecol Can. 2012 Nov;34(11):1077-1086. [PubMed: 23231846]
60.Burch HB, Cooper DS. ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later. Eur J Endocrinol. 2018 Oct 12;179(5):R261-R274. [PubMed: 30320502]
61.Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med. 1994 Aug 15;121(4):281-8. [PubMed: 7518659]
62.Mohlin E, Filipsson Nyström H, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010. Eur J Endocrinol. 2014 Mar;170(3):419-27. [PubMed: 24366943]
63.Komiya I, Yamada T, Sato A, Kouki T, Nishimori T, Takasu N. Remission and recurrence of hyperthyroid Graves’ disease during and after methimazole treatment when assessed by IgE and interleukin 13. J Clin Endocrinol Metab. 2001 Aug;86(8):3540-4. [PubMed: 11502776]
64.Suzuki N, Noh JY, Yoshimura R, Mikura K, Kinoshita A, Suzuki A, Mitsumatsu T, Hoshiyama A, Fukushita M, Matsumoto M, Yoshihara A, Watanabe N, Sugino K, Ito K. Does Age or Sex Relate to Severity or Treatment Prognosis in Graves’ Disease? Thyroid. 2021 Sep;31(9):1409-1415. [PubMed: 33882721]
65.Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001 Aug;86(8):3611-7. [PubMed: 11502786]
66.Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (¹³¹I) doses for Graves disease treatment. Clin Nucl Med. 2012 Mar;37(3):241-4. [PubMed: 22310249]
67.Roque C, Santos FS, Pilli T, Dalmazio G, Castagna MG, Pacini F. Long-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity. J Clin Endocrinol Metab. 2020 Jul 01;105(7) [PubMed: 32320467]
68.Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goiter with hyperthyroidism (Plummer’s disease): surgery versus radioiodine. Surgery. 2002 Dec;132(6):916-23; discussion 923. [PubMed: 12490836]
69.Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med. 1982 Feb;23(2):103-7. [PubMed: 7057248]
70.Yano Y, Sugino K, Akaishi J, Uruno T, Okuwa K, Shibuya H, Kitagawa W, Nagahama M, Ito K, Ito K. Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy. Ann Nucl Med. 2011 Dec;25(10):749-754. [PubMed: 21971604]
71.Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999 Jun 28;159(12):1364-8. [PubMed: 10386513]
72.Ferrari C, Reschini E, Paracchi A. Treatment of the autonomous thyroid nodule: a review. Eur J Endocrinol. 1996 Oct;135(4):383-90. [PubMed: 8921817]
73.Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol (Oxf). 2005 Mar;62(3):331-5. [PubMed: 15730415]
74.Erbil Y, Ozluk Y, Giriş M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmağan S, Tezelman S. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007 Jun;92(6):2182-9. [PubMed: 17389702]
75.Ansaldo GL, Pretolesi F, Varaldo E, Meola C, Minuto M, Borgonovo G, Derchi LE, Torre GC. Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol’s iodide solution in patients with diffuse toxic goiter. J Am Coll Surg. 2000 Dec;191(6):607-12. [PubMed: 11129808]
76.Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf). 2013 Nov;79(5):739-46. [PubMed: 23521078]
77.Limonard EJ, Bisschop PH, Fliers E, Nieveen van Dijkum EJ. Thyroid function after subtotal thyroidectomy in patients with Graves’ hyperthyroidism. ScientificWorldJournal. 2012;2012:548796. [PMC free article: PMC3290451] [PubMed: 22448136]
78.Al-Adhami A, Snaith AC, Craig WL, Krukowski ZH. Changing trends in surgery for Graves’ disease: a cohort comparison of those having surgery intended to preserve thyroid function with those having ablative surgery. J Otolaryngol Head Neck Surg. 2013 May 29;42(1):37. [PMC free article: PMC3681644] [PubMed: 23718902]
79.Dogan L, Karaman N, Yilmaz KB, Ozaslan C, Atalay C. Total thyroidectomy for the surgical treatment of multinodular goiter. Surg Today. 2011 Mar;41(3):323-7. [PubMed: 21365410]
80.Hussain M, Hisham AN. Total thyroidectomy: the procedure of choice for toxic goitre. Asian J Surg. 2008 Apr;31(2):59-62. [PubMed: 18490216]
81.Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004 Nov;14(11):933-45. [PubMed: 15671772]
82.Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Ito K, Taniyama M. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012 Aug;77(2):310-5. [PubMed: 22332800]
83.Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014 Sep;78(3):619-29. [PMC free article: PMC4243912] [PubMed: 25279406]
84.Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013 Dec;98(12):4776-83. [PubMed: 24057289]
85.Noh JY, Yasuda S, Sato S, Matsumoto M, Kunii Y, Noguchi Y, Mukasa K, Ito K, Ito K, Sugiyama O, Kobayashi H, Nihojima S, Okazaki M, Yokoyama S. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab. 2009 Aug;94(8):2806-11. [PubMed: 19491223]
86.Gao Y, Zhao MH, Guo XH, Xin G, Gao Y, Wang HY. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res. 2004 May;30(2):205-13. [PubMed: 15473130]
87.Yazisiz V, Ongüt G, Terzioğlu E, Karayalçin U. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract. 2010 Jan;64(1):19-24. [PubMed: 18284438]
88.Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum. 2006 Aug;36(1):4-9. [PubMed: 16887463]
89.Hess E. Drug-related lupus. N Engl J Med. 1988 Jun 02;318(22):1460-2. [PubMed: 3259288]
90.Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, Menon R, Chen M. Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes. 2012 Dec;13(8):652-5. [PubMed: 22759245]
91.Jain N, Savani M, Agarwal M, Kadaria D. Methimazole-induced insulin autoimmune syndrome. Ther Adv Endocrinol Metab. 2016 Aug;7(4):178-81. [PMC free article: PMC4973408] [PubMed: 27540463]
92.Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo MR, Pezzullo L. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg. 2004 Mar;28(3):271-6. [PubMed: 14961204]
93.Bhattacharyya N, Fried MP. Assessment of the morbidity and complications of total thyroidectomy. Arch Otolaryngol Head Neck Surg. 2002 Apr;128(4):389-92. [PubMed: 11926912]
94.Safioleas M, Stamatakos M, Rompoti N, Mouzopoulos G, Iannescu R, Salichou V, Skandalakis P. Complications of thyroid surgery. Chirurgia (Bucur). 2006 Nov-Dec;101(6):571-81. [PubMed: 17283832]
95.Thiyagarajan A, Platzbecker K, Ittermann T, Völzke H, Haug U. Estimating Incidence and Case Fatality of Thyroid Storm in Germany Between 2007 and 2017: A Claims Data Analysis. Thyroid. 2022 Nov;32(11):1307-1315. [PubMed: 36006371]
96.Dekkers OM, Horváth-Puhó E, Cannegieter SC, Vandenbroucke JP, Sørensen HT, Jørgensen JO. Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study. Eur J Endocrinol. 2017 Jan;176(1):1-9. [PubMed: 27697972]
97.Abrahamsen B, Jørgensen HL, Laulund AS, Nybo M, Bauer DC, Brix TH, Hegedüs L. The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis. J Bone Miner Res. 2015 May;30(5):898-905. [PubMed: 25431028]
98.Mintziori G, Kita M, Duntas L, Goulis DG. Consequences of hyperthyroidism in male and female fertility: pathophysiology and current management. J Endocrinol Invest. 2016 Aug;39(8):849-853. [PubMed: 26956000]
99.Siu CW, Pong V, Zhang X, Chan YH, Jim MH, Liu S, Yiu KH, Kung AW, Lau CP, Tse HF. Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm. 2009 Feb;6(2):169-73. [PubMed: 19187905]
100.Xu N, Wang Y, Xu Y, Li L, Chen J, Mai X, Xu J, Zhang Z, Yang R, Sun J, Chen H, Chen R. Effect of subclinical hyperthyroidism on osteoporosis: A meta-analysis of cohort studies. Endocrine. 2020 Jul;69(1):39-48. [PubMed: 32207036]
101.Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N., Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012 May 28;172(10):799-809. [PMC free article: PMC3872478] [PubMed: 22529182]
102.Abdulaziz Qari F. Thyroid Hormone Profile in Patients With Acute Coronary Syndrome. Iran Red Crescent Med J. 2015 Jul;17(7):e26919. [PMC free article: PMC4584079] [PubMed: 26421178]
103.Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat Rev Endocrinol. 2017 Oct;13(10):610-622. [PubMed: 28776582]
104.Samuels SL, Namoc SM, Bauer AJ. Neonatal Thyrotoxicosis. Clin Perinatol. 2018 Mar;45(1):31-40. [PubMed: 29406005]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *